Model-Informed Drug Development of the Masked Anti-PD-L1 Antibody CX-072
Collaboration with CytomX Therapeutics - Published in Clinical Pharmacology & Therapeutics
Abstract
CX‑072 is an anti‑PD‑L1 (programmed death ligand 1) Probody therapeutic (Pb‐Tx) designed to be preferentially activated by proteases in the tumor microenvironment and not in healthy tissue. Here, we report the model‐informed drug development of CX‐072. A quantitative systems pharmacology (QSP) model that captured known mechanisms of Pb‐Tx activation, biodistribution, elimination, and target engagement was used to inform clinical translation.